New real-world data compares two paths for cardiovascular outcomes: stepping up the semaglutide dose or moving patients over to tirzepatide.
Recap by typeshit. Post by @medicalupdateonline on Instagram.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
BusinessWorld Online makes the case that Ozempic shouldn't be thought of as a weight loss drug. Only the headline was available, so tap through for the full argument.
Novo is putting oral treatments and more personalized options first as the market moves past raw weight loss numbers, the CEO told Chosun Ilbo.
Loading…